GlobeNewswire

Saniona publishes its interim report for the second quarter of 2021

Share

PRESS RELEASE

August 26, 2021

Three Months Ended June 30, 2021 (2020)
Revenue was SEK 1.9 M (2.0 M)
Operating loss was SEK -103.6 M (-26.0 M)
Net profit/loss was SEK -103.9 M (-23.9 M)
Basic loss per share was SEK -1.67 (-0.81)
Diluted loss per share was SEK -1.67 (-0.81)

Six Months Ended June 30, 2021 (2020)
Revenue was SEK 5.3 M (4.4 M)
Operating loss was SEK -197.7 M (-53.5 M)
Net profit (loss) was SEK -187.3 M (19.3 M)
Basic earnings (loss) per share was SEK -3.00 (0.65)
Diluted earnings (loss) per share was SEK -3.00 (0.65)

Business highlights in Q22021

  • Saniona achieved a key milestone with the initiation ofa Phase 1 clinical trial of SAN711, an ion channel modulator that may be applicable in the treatment of rare neuropathic disorders. This is the first wholly-owned asset from Saniona's proprietary ion channel drug discovery engine to advance into a clinical trial. Data from the trial are expected in the first half of 2022.
  • Saniona provided multiple updates on its progress toward initiating Phase 2b clinical trials of Tesomet in hypothalamic obesity (HO) and Prader-Willi syndrome (PWS), announcing a partnership with the Foundation for Prader-Willi Research to increase clinical trial awareness and the receipt of manufacturing feedback from the U.S. Food and Drug Administration (FDA) on the transition from tablets to capsules. Both Phase 2b clinical trials are expected to start in the second half of 2021, with top-line data expected from the PWS clinical trial in the first half of 2023 and from the HO clinical trial in the second half of 2023.
  • Saniona presented preclinical data from its ion channel program SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting. SAN903 is expected to enter Phase 1 in the second half of 2022. Saniona also presented SAN711 preclinical data in a model of facial neuropathic pain at the prestigious European Academy of Neurology (EAN) Congress.
  • Saniona hosted a Research and Development (R&D) day featuring presentations highlighting its ion channel drug discovery engine, including its IONBASE™ database now consisting of more than 20,000 proprietary molecules targeting various ion channels.
  • Saniona provided an update from its partner Medix that additional information requested by a Mexican regulatory committee may delay the anticipated final decision in Mexico regarding tesofensine for obesity into 2022.
  • Saniona successfully monetized its position in the 2017 spin-out Scandion Oncology, completing the sale of its remaining shares on the open market.
  • Saniona received a minority ownership stake in Cephagenix, as per the terms of the previously announced February 2020 collaboration agreement through which the company was formed to explore ion channel modulators for the treatment of migraine.

Significant events after the reporting period

  • Saniona achieved orphan drug designation from the FDA for Tesomet for the treatment of HO. Tesomet is the first and only investigational treatment for HO to receive orphan drug designation.
  • Saniona entered into a non-dilutive term loan agreement for SEK 87 million ($10 million) with Formue Nord Fokus A/S to support new activities aimed at accelerating clinical development programs.

Comments from the CEO
"In the first half of 2021 and into the subsequent period, Saniona has made significant progress on the clinical and regulatory fronts, achieving orphan drug designations from the U.S. FDA for Tesomet in both hypothalamic obesity and Prader-Willi syndrome. These designations put us in a strong position as we prepare to initiate our Phase 2b trials of Tesomet in HO and PWS before the end of this year,” said Rami Levin, President & Chief Executive Officer of Saniona. “Additionally, in Q2 we initiated a Phase 1 clinical trial of SAN711, our second wholly-owned proprietary pipeline asset to advance into clinical trials. SAN711 is our lead molecule from our ion channel drug discovery engine, which has already generated a number of additional discovery-stage and preclinical assets to fuel our pipeline well into the future.”

Read the full report attached below.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulationand the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on August 26, 2021.

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for patients suffering from rare diseases for which there are a lack of available treatment options. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE, Saniona’s database of more than 130,000 ion channel modulators, of which more than 20,000 are Saniona’s proprietary compounds. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Led by an experienced scientific and operational team, Saniona has an established research organization in the Copenhagen area, Denmark, and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nordic American Tankers Ltd (NYSE: NAT) – Purchase of NAT shares by Herbjorn Hansson, Founder, Chairman & CEO of NAT17.9.2021 15:41:35 CEST | Press release

Friday, September 17 , 2021 Dear Shareholders and Investors, Herbjorn Hansson has today bought 75,000 shares in NAT at USD 2.3273 per share. As in the past, the Hansson family is one of the largest shareholders in NAT. Sincerely, Herbjorn Hansson Founder, Chairman & CEO Nordic American Tankers Ltd. www.nat.bm CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)17.9.2021 13:30:00 CEST | Press release

PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death Alpelisib is the first potential treatment to specifically address the root cause of PROS conditions EPIK-P1 study findings presented at ESMO Virtual Congress 2021 support FDA submission Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Resu

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS17.9.2021 13:15:00 CEST | Press release

Mechelen, Belgium;17September 2021;13.15 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced todaythatthe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issueda positive opinion for Jyseleca® (filgotinib), a once-daily, oral, JAK1preferential inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Following this positive opinion, a final decision from the European Commission is expected later this year. The CHMP positive opinion is based on data from the pivotal Phase 2b/3 SELECTION program, which evaluated filgotinib as an induction and maintenance therapy in adult patients with moderately to severely active UC who have failed conventional therapy or biologics. SELECTION comprised two placebo-controlled induction studies, one in biologic-naive patients and the o

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer17.9.2021 13:10:00 CEST | Press release

Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. “This positive CHMP opinion for Gavreto represents another important step towards our goal of providing effective therapeutics that target genomic drivers of disease for as many cancer patients as possible," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Developmen

Elina Stråhlman appointed as Enento Group’s acting CEO17.9.2021 13:00:00 CEST | Press release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 17 SEPTEMBER 2021 AT 2.00 P.M. EEST Elina Stråhlman appointedas Enento Group’s acting CEO As communicated with a stock exchange release on 21 April 2021, Enento Group Plc’s current CEO Jukka Ruuska has given notice of his resignation from the company no later than 31 October 2021. As announced in July, Jeanette Jäger will start as the new CEO and member of the Executive Management Team on 1 January 2022. Since 2016 she has worked in the Swedish company Bankgirot, first as VP Digital Services and from 2017 as CEO of Bankgirot. Enento Group's Board of Directors has today appointed Elina Stråhlman, the Group’s CFO, as an acting CEO for the interim period from 1 November 2021 to 31 December 2021. ENENTO GROUP PLC For further information: Jukka Ruuska CEO Tel. +358 10 270 7111 Distribution: Nasdaq Helsinki Major media enento.com/investors Enento Group is a Nordic knowledge company powering society with intelligence since 1905. We collect and trans

Fobi Launches Connected Retail Commerce Solution At Industry’s Premier Event For Convenience, Grocers and CPG Brands17.9.2021 12:00:00 CEST | Press release

Fobi CEO Rob Anson and Senior Vice President of Business Development Mike Canevaro to launch new Personalized Digital Receipt Marketing Solution at GroceryShop to be held September 19-22 in Las Vegas, Nevada VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSX.V: FOBI) (OTCQB: FOBIF) (the "Company" or "Fobi"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is excited to announce the launch of its latest solution. The Fobi connected retail commerce solution will support real-time POS data connectivity across all banners and channels, in-store, online and mobile to provide retailers and CPG manufacturers with the ability to deliver automated and personalized marketing at scale. PERSONALIZED MARKETING TO EMPOWER CPG BRANDS BY PROVIDING THEM WITH DIRECT ACCESS TO ENGAGE CONSUMERS WITH PROMOTIONS AND CAMPAIGN ACTIVATION MEASUREMENT Fobi will now enable manufacturer brands to gain

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 10:07:00 CEST | Press release

Auction date2021-09-17Loan1059Coupon1.00 %ISIN-codeSE0007125927Maturity2026-11-12Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,000Volume bought, SEK mln500Number of bids2Number of accepted bids1Average yield-0.028Lowest accepted yield-0.028Highest yield-0.028% accepted at lowest yield 100.00 Auction date2021-09-17Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 350Volume offered, SEK mln1,750Volume bought, SEK mln750Number of bids5Number of accepted bids1Average yield0.277Lowest accepted yield0.277Highest yield0.277% accepted at lowest yield 100.00